Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.

doi:10.1200/JCO.2012.47.8313

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Back to search

Article

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Sept 2013

Phillips Kelly-Anne, Milne Roger L, Rookus Matti A, Daly Mary B, Antoniou Antonis C, Peock Susan, Frost Debra, Easton Douglas F, Ellis Steve, Friedlander Michael L, Buys Saundra S, Andrieu Nadine, Noguès Catherine, Stoppa-Lyonnet Dominique, Bonadona Valérie, Pujol Pascal, McLachlan Sue Anne, John Esther M, Hooning Maartje J, Seynaeve Caroline, Tollenaar Rob A E M, Goldgar David E, Terry Mary Beth, Caldes Trinidad, Weideman Prue C, Andrulis Irene L, Singer Christian F, Birch Kate, Simard Jacques, Southey Melissa C, Olsson Håkan L, Jakubowska Anna, Olah Edith, Gerdes Anne-Marie, Foretova Lenka, Hopper John L

Abstract excerpt

PURPOSE: To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 mutation carriers. METHODS: Analysis of pooled observational cohort data, self-reported at enrollment and at follow-up from the International BRCA1, and BRCA2 Carrier Cohort Study, Kathleen Cuningham Foundation Consortium for Research into...

Topics

Adult
Aged
Breast Neoplasms
Estrogen Antagonists
Female
Genes, BRCA1
Genes, BRCA2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Heterozygote

Humans

Middle Aged

Mutation

Proportional Hazards Models

Risk Factors

Tamoxifen

Source

Open in PubMed Open full text

Identifiers

PMID: 23918944
DOI: 10.1200/JCO.2012.47.8313
PMCID: PMC3753701

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.PMID 23918944Read ↗

Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update.Semantic proximity Read ↗

Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis.Semantic proximity Read ↗

Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.Semantic proximity Read ↗

Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.Semantic proximity Read ↗

Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.Semantic proximity Read ↗

Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers.Semantic proximity Read ↗

Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Triple negative status and BRCA mutations in contralateral breast cancer: a population-based study.Semantic proximity Read ↗

Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation.Semantic proximity Read ↗

The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling.Semantic proximity Read ↗

Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.